08 Jun 06
Osteoarthritis is the leading cause of disability in the US, and is estimated to be the eighth most common cause of disability worldwide, with around 89 million adults in the seven major markets having a form of symptomatic osteoarthritis. OA therefore offers an attractive commercial target. However, relatively low disease awareness and Cox-2s controversy have curbed the market's potential so far.
07 Jun 06
DailyUpdates 7th June: ASCO is finished for this year now but not before Gloucester Pharmaceuticals managed to counter yesterday’s news from Merck with clinical data on their own HDAC inhibitor. Together this means that the two most advanced HDAC inhibitors are progressing nicely towards the market and soon, we hope, cancer patients will be offered another option. Also today we report on Pfizer’s very early stage serotonin 5-HT receptor ligands, a class that is emerging from the arena of IBS to
05 Jun 06
(The American Society of Clinical Oncology) now in full swing, cancer is not surprisingly the focus of today's news section and out of the 20 or so press releases featured we highlight and announcement by Cell Genesys describing the development of their GVAX vaccine for the treatment of CML. In their phase 2 trial the company reports that a complete molecular response is seen in 25% of patients whose treatment included GVAX - this compares to historical data of about 10% in patients not receivin
02 Jun 06
Psychiatrists attending this year’s Annual Psychiatric Association meeting heard new findings from the controversial CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) programme. New data suggest an older typical antipsychotic drug is more cost effective and has the same cognitive benefits as newer atypical drugs. Previous results suggested the older first generation drug is equally effective and well-tolerated clinically, compared to newer atypicals but the study design was m
Olwen Glynn Owen - PharmiWeb Field Reporter
31 May 06
DailyUpdates 26th May, 2006: As our daily trip around the drug discovery world continues we hit Friday with some revealing information on sepsis and new phase 3 data on Wyeth's antidepressant desvenlafaxine. Read on for more about these highlight on visit today's edition of DailyUpdates for more on these advances or any of the other 50+ items featured today
31 May 06
EntreMed has initiated a phase II trial of Panzem in combination with Genentech's Avastin in carcinoid cancer. The trial will examine how the therapy fares against potential rivals and its possible use in other tumor types. With the blockbuster Avastin possessing the potential to significantly raise the profile of Panzem, the study will prove crucial for EntreMed's lead pipeline drug candidate.
30 May 06
DailyUpdates 30th May: As the drug discovery sector returns after various public holidays around the world, we too return with another edition of DailyUpdates. Amongst the 60 or so features today, we highlight work at Kane Biotech conducted in an attempt to reduce the major problem of catheter infection, plus news on the development of a liposomal candidate designed to deliver the active metabolite of Camptosar to colorectal cancer tumors. Summaries of this work are provided below - today's edit
26 May 06
Although ventricular and atrial fibrillation represent the most common cardiac arrhymias and are associated with amongst the highest rates of cardiovascular morbidity and mortality, treatment options are suboptimal. New opportunities are however approaching the market, notably Cardiome’s RSD1235, paving the way for development by others.
26 May 06
DailyUpdates 25th May, 2006: Today both featured items from DailyUpdates focus on autoimmune disease and remarkably neither are biologics. The first, a press release from Synta announces the advancement of an IL-12/IL-23 inhibitor in development for rheumatoid arthritis and IBD; the second is a review of potassium channels as targets for the treatment of multiple sclerosis.
24 May 06
DailyUpdates 24th May, 2006: With the threat of influenza hanging over our heads on a seemingly continuous basis, improving the ability to rapidly and accurately identify patients infected with influenza and furthermore the strain of virus remains paramount. Today we feature research from CombiMatrix concerning their activities in this area. We also headline news coming out of Denmark's Genmab announcing the advance of HuMax-CD20, the company's CD20 monoclonal, into the clinic for the treatment
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.